More patients in the necitumumab plus gemcitabine and cisplatin group had grade @-@ hypomagnesaemia ( @ -LSB- @ % -RSB- of @ patients in the necitumumab plus gemcitabine and cisplatin group vs six -LSB- @ % -RSB- of @ in the gemcitabine and cisplatin group ) and grade @ rash ( @ -LSB- @ % -RSB- vs one -LSB- < @ % -RSB- ) .